

**Shilpa Biologicals Private Limited**  
**Balance Sheet as at 31st March,2021**

(All amounts are in Indian Rupees except share data and per share data, unless otherwise stated)

Particulars	Notes	Audited	Unaudited	Audited
		31.03.2021	31.12.2020	31.03.2020
<b>ASSETS</b>				
<b>Non- current assets</b>				
(a) Property, plant & equipment.	3	3,09,43,47,089	20,68,21,206	22,75,18,068
(b) Right of use - Lease Assets		3,84,27,865	3,89,37,478	3,92,43,247
(c) Capital work- in- progress	4	6,46,41,429	2,89,94,44,015	2,35,08,88,003
(d) Goodwill on Merger		26,53,05,579	26,53,05,579	26,53,05,579
(e) Intangible assets	5	7,39,65,259	5,05,47,793	6,36,52,115
(f) Intangible assets under development	6	46,10,00,700	48,77,90,652	48,72,52,652
(g) Financial assets				
- Other financial assets	7	72,72,744	60,65,581	36,64,892
(h) Deferred tax Assets	16	1,36,59,049		-
(i) Other non-current assets	8	4,90,99,642	5,00,61,825	3,05,44,547
<b>Total</b>		<b>4,06,77,19,355</b>	<b>4,00,49,74,130</b>	<b>3,46,80,69,103</b>
<b>Current assets</b>				
(a) Inventories	9	11,73,73,701	10,91,66,241	5,69,33,329
(b) Financial assets	10			
(i) Trade receivables		9,52,505	18,51,586	38,160
(ii) Cash and cash equivalents		3,16,55,013	5,35,66,270	6,56,72,721
(iii) Others financial assets		17,88,076	5,88,875	6,06,960
(c) Other current assets	11	30,25,13,993	29,02,11,427	14,70,29,985
		<b>45,42,83,289</b>	<b>45,53,84,399</b>	<b>27,02,81,155</b>
<b>TOTAL ASSETS</b>		<b>4,52,20,02,644</b>	<b>4,46,03,58,529</b>	<b>3,73,83,50,258</b>
<b>EQUITY AND LIABILITY</b>				
<b>Equity</b>				
(a) Equity share capital	12	30,00,00,000	30,00,00,000	1,00,000
(b) Other equity	13	(31,26,81,411)	(25,06,74,538)	(28,66,87,223)
		<b>(1,26,81,411)</b>	<b>4,93,25,462</b>	<b>(28,65,87,223)</b>
<b>LIABILITIES</b>				
<b>Non- current liabilities</b>				
(a) Financial Liabilities	14			
(i) Borrowings		3,74,25,93,823	3,63,32,93,823	53,48,623
(b) Provisions	15	46,49,198	77,18,524	41,64,896
(c) Deferred Tax Liabilities (Net)	16	-	9,44,65,538	20,14,35,153
(d) Other Financial Liability	17	16,84,15,549	18,18,56,666	18,25,80,017
		<b>3,91,56,58,570</b>	<b>3,91,73,34,551</b>	<b>39,35,28,689</b>
<b>Current liabilities</b>				
(a) Financial Liabilities	18			
(i) Trade Payables				
-Total Outstanding dues of micro & Small Enterprises.		4,32,48,182	4,81,30,112	5,27,71,705
-Total Outstanding dues of other than micro & Small Enterprises.		4,34,95,888	4,90,03,985	41,891
(ii) Other Financial liabilities	19	50,35,93,676	38,25,36,607	3,55,88,91,256
(b) Other Liabilities	20	1,96,51,223	52,56,542	1,36,67,701
(c) Provisions	21	90,36,515	87,71,270	60,36,244
		<b>61,90,25,484</b>	<b>49,36,98,516</b>	<b>3,63,14,08,795</b>
<b>TOTAL EQUITY &amp; LIABILITY</b>		<b>4,52,20,02,644</b>	<b>4,46,03,58,529</b>	<b>3,73,83,50,259</b>

**Shilpa Biologicals Private Limited**
**Statement of Profit and Loss for the Year ended March 31, 2021**

(All amounts are in Indian Rupees, share data and earning per share, unless otherwise stated)

Particulars	Notes	Audited	Unaudited	Audited
		For the year ended 31st March 2021	For the 9 months ended Dec 31st 2020	For the year ended 31st March 2020
<b>Revenue</b>				
(a) Revenue from operations		8,03,000	-	-
Less: Excise duty		-	-	-
(b) Other operating revenues		-	-	-
<b>Revenue from continuing operations</b>		<b>8,03,000</b>	-	-
(c) Other Income	22	60,93,178	8,68,842	-
<b>Total (Income)</b>		<b>68,96,178</b>	<b>8,68,842</b>	-
<b>Expenses</b>				
<b>Expenses</b>				
(a) Cost of materials consumed		-	-	-
(b) Purchases of stock-in trade		-	-	-
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade		-	-	-
(d) Employee benefits expense	23	11,34,30,225	5,55,71,413	-
(e) Finance costs	24	3,70,75,736	2,05,476	-
(g) Depreciation	5	6,38,53,158	2,70,97,983	-
(h) Other expenses	25	7,05,36,593	2,50,44,359	27,17,200
<b>Total Expenses</b>		<b>28,48,95,712</b>	<b>10,79,19,231</b>	<b>27,17,200</b>
Profit before Exceptional item and tax Exceptional (income) / expense		(27,79,99,533)	(10,70,50,389)	(27,17,200)
<b>Profit Before Tax/(Loss)</b>		<b>(27,79,99,533)</b>	<b>(10,70,50,389)</b>	<b>(27,17,200)</b>
<b>Tax Expenses</b>				
a) Current Tax		-	-	-
b) Deferred Tax Asset / (Liability)		21,50,94,202	10,69,69,615	8,45,33,798
Less: Mat Credit Entitlement		-	-	-
Net Deferred Tax		21,50,94,202	10,69,69,615	8,45,33,798
Total tax expenses	-	<b>21,50,94,202</b>	<b>10,69,69,615</b>	<b>8,45,33,798</b>
<b>Profit/(Loss) for the year</b>	-	<b>(6,29,05,332)</b>	<b>(80,775)</b>	<b>8,18,16,598</b>
<b>Other comprehensive (Income) / Expenses</b>				
<b>(i) Items that will not be reclassified subsequently to profit or loss</b>				
Remeasurement of post employment benefit obligations		8,17,685	-	-
<b>(ii) Items that will be reclassified subsequently to profit or loss</b>				
Effective portion of gains/(losses) on hedging instrument in cash flow hedges ( net of tax )		-	-	-
<b>Total comprehensive income /(loss)</b>	-	<b>(6,20,87,647)</b>	<b>(80,775)</b>	<b>8,18,16,598</b>
<b>Earning per equity share for Rs.100/- face value (Continued Operations)</b>				
Basic	31	(26.68)	(0.03)	81,816.60
Diluted		(26.68)	(0.03)	81,816.60
<b>Number of shares used in computing earnings per share (Continued Operations)</b>				
Basic		23,57,586	30,00,000	1,000
Diluted		23,57,586	30,00,000	1,000



**Shilpa Biologicals Private Limited**

**Notes to the forming part of Financial statement for the perior ended 31st March, 2021**

(All amounts are in Indian Rupees except shares date and per share date, unless otherwise stated )

**4 Tangible assets under development**

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
<b>(a) Tangible assets under development</b>			
i) Machinery under erection	74,000	42,21,558	-
ii) Lab Equipment Under Erection	-	-	-
iii) Projects under erection	5,29,92,429	2,07,20,61,800	1,96,86,97,625
iv) Pre-operative expenses	0	82,31,60,657	38,21,90,377
<b>(b) In-tangible assets under development</b>			
i) Development study expenses	1,15,75,000	-	-
<b>TOTAL (a)+(b)</b>	<b>6,46,41,429</b>	<b>2,89,94,44,015</b>	<b>2,35,08,88,003</b>

**6 Intangible Assets under Development**

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
i) Software under Installation	-	22,86,950	17,48,950
ii) Products under Development	46,10,00,700	48,55,03,702	48,55,03,702
<b>TOTAL</b>	<b>46,10,00,700</b>	<b>48,77,90,652</b>	<b>48,72,52,652</b>

**7 Other Financial Assets**

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
<b>(a) Security deposits (unsecured considered good) (Refer Note No.35)</b>			
(i) Electricity deposits	32,88,863	32,88,863	32,88,863
(ii) Telephone deposits	26,529	26,529	26,529
(iii) Miscellaneous deposits	3,49,500	3,49,500	3,49,500
iv) Deposit-Others	9,440	9,440	-
<b>(b) Interest accrued but not due on deposit placed as Margin money</b>	35,98,412	23,91,249	-
	72,72,744	60,65,581	36,64,892
Less: Provision for Doubtful Deposits	-	-	-
<b>TOTAL (a)+(b)</b>	<b>72,72,744</b>	<b>60,65,581</b>	<b>36,64,892</b>

**8 Other non-current assets**

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
<b>a) Capital advances (Refer Note No.35)</b>			
(i) Unsecured, considered good	1,71,61,614	1,81,11,611	3,00,86,758
Less: Written off	-	-	-
<b>TOTAL (a)</b>	<b>1,71,61,614</b>	<b>1,81,11,611</b>	<b>3,00,86,758</b>
<b>b) Others</b>			
i) Prepaid Expenses	33,56,901	24,57,243	2,21,789
ii) Others (Refer Note No. 26)	-	2,36,000	2,36,000
iii) GST Receivable	-	-	-
(iv) Deferred Finance Cost- Related party	2,82,88,186	2,91,55,439	-
(v) TDS receivable	2,92,941	1,01,532	-
<b>TOTAL (b)</b>	<b>3,19,38,028</b>	<b>3,19,50,213</b>	<b>4,57,789</b>
<b>TOTAL (a+b)</b>	<b>4,90,99,642</b>	<b>5,00,61,825</b>	<b>3,05,44,547</b>

**9 Inventories**

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
(a) Consumables	7,46,46,912	10,91,66,241	5,69,33,329
(b) Raw Materials	1,88,86,581	-	-
(c) Packing materials	1,23,32,034	-	-
(d) Stores and Spares *	1,15,08,174	-	-
<b>Total</b>	<b>11,73,73,701</b>	<b>10,91,66,241</b>	<b>5,69,33,329</b>

\* After provision made towards Expired inventory ( INR 488,033/-)

**10 Financial Assets**

**(i) Trade Receivables (Note No.35)**

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
Secured considered good	9,44,000	18,43,586	-
Unsecured considered good	8,505	8,000	38,160
doubtful	-	-	-
	9,52,505	18,51,586	38,160
Less: Allowance for doubtful debts	-	-	-
<b>TOTAL (a+b)</b>	<b>9,52,505</b>	<b>18,51,586</b>	<b>38,160</b>

Note: Trade Receivable in the above Note no. 10(i) includes INR 9,44,000/ (PY - Nil) is receivable from related parties (Refer Note No. 26 from Related party transaction.

**(ii) Cash and cash equivalents**

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
i) Cash on Hand	64,349	72,711	85,534
ii) Balance with Banks in Current Account	3,15,90,664	5,34,93,559	6,55,87,187
<b>TOTAL</b>	<b>3,16,55,013</b>	<b>5,35,66,270</b>	<b>6,56,72,721</b>

**(iii) Others**

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
(i) Staff advance	17,88,076	5,88,875	6,06,960
<b>TOTAL</b>	<b>17,88,076</b>	<b>5,88,875</b>	<b>6,06,960</b>

**11 Others current assets**

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
(i) Advances to Supplier/ Receivables	15,30,141	6,98,678	4,10,590
(ii) CGST /IGST /SGST Receivable ( Refer Note No.38)	20,09,83,851	18,95,12,749	14,66,19,395
iii) Fixed Deposit against margin money with Bank *	10,00,00,000	10,00,00,000	-
	30,25,13,993	29,02,11,427	14,70,29,985
Add: Considered Doubtful			
	30,25,13,993	29,02,11,427	14,70,29,985
Less: Written-off			
<b>TOTAL</b>	<b>30,25,13,993</b>	<b>29,02,11,427</b>	<b>14,70,29,985</b>

\* Deposit placed as security with HDFC bank against Term loan

**13 Other Equity**

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
<b>(a) Capital Reserve</b>			
Opening Balance	(36,85,03,821)	(36,58,24,621)	(36,85,03,821)
Add: Addition during the period	-	-	-
Less: Amount utilized	-	-	-
<b>Closing Balance</b>	<b>(36,85,03,821)</b>	<b>(36,58,24,621)</b>	<b>(36,85,03,821)</b>
<b>(b) Fair Value of Corporate Gurantee</b>			
Add: Fair value of Corporate Gurantee	3,60,93,459	3,60,93,459	-
<b>Closing Balance</b>	<b>3,60,93,459</b>	<b>3,60,93,459</b>	<b>-</b>
<b>(c) Retained Earnings</b>			
Opening Balance	8,18,16,599	7,91,37,399	-
Add: Profit/ ( Loss) for the period	(6,20,87,647)	(80,775)	8,18,16,598
<b>Amount available for appropriations</b>	<b>1,97,28,952</b>	<b>7,90,56,624</b>	<b>8,18,16,598</b>
<b>TOTAL</b>	<b>(31,26,81,411)</b>	<b>(25,06,74,538)</b>	<b>(28,66,87,223)</b>

**14 Financial liabilities****(i) Long term borrowings**

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
<b>Term loans (Secured)</b>			
<b>From banks</b>			
Term Loan- HDFC C/A No:- <b>Terms</b> The term loan was sanctioned by the bank on 25th June 2020 The said loan was originally repayable in 4 years and 11 months starting from 30th June 2021. However, the bank has revised the start date of repayment of loan from 30.06.2021 to 30.08.2021, without changing the number of repayment instalments. The term loans is secured by way of first charge on the entire fixed assets of the company (both present and future) and Corporate Gurantee from Shilpa Medicare Limited (Holding Co) and personal gurantee of Managing Director of the company. <b>Rate of Interest</b> The term loan has been granted at 7.1% linked to repo rate to be reprised every 3 months. Interest is payable on a monthly basis.	1,21,87,50,000	1,31,25,00,000	-
<b>From Others (Unsecured)</b>			
<b>Holding company</b>			
a) Shilpa Medicare Limited Term loan from Holding company has been taken at @ 7.50% interest per annum. The loan is re-payable over a period of 8 years including moratorium of 5 years. The repayment will made in 12 Quarterly instalments including interest accrued there on, starting from 1st September 2025.	2,52,06,00,001	2,31,75,50,001	-
b) Loan under SIBIRI Scheme <b>Nature</b> Loan from Department of Biotechnology, Ministry of Science and Technology New Delhi. Under Scheme Small Business Innovative Research Initiative (SIBIRI). <b>Terms of Repayment &amp; Interest Rate:</b> The Loan is repayable is 10 equal yearly instalment starting from 17.08.2013 of Rs 21.048 Lakhs with final instalment falling due on 17.08.2022. Interest is payable @ 1% P.A on amount drawn upto Rs 100 Lakhs and @ 2% above Rs 100 Lakhs, and is payable in 02 equal installment after principal repayment.	32,43,823	32,43,823	53,48,623
<b>TOTAL</b>	<b>3,74,25,93,823</b>	<b>3,63,32,93,823</b>	<b>53,48,623</b>

15 Provision			
Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
(i) Provision for gratuity ( Refer Note No. 27)	46,49,198	77,18,524	41,64,896
<b>TOTAL</b>	<b>46,49,198</b>	<b>77,18,524</b>	<b>41,64,896</b>

16 Deferred tax liability / (Assets) (net)			
Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
(i) Deferred tax liability (Refer Note No.32)	9,72,61,448	12,39,21,838	20,90,74,767
(ii) Deferred tax asset (Refer Note No.32)	(11,09,20,497)	(2,94,56,300)	(76,39,614)
<b>TOTAL</b>	<b>(1,36,59,049)</b>	<b>9,44,65,538</b>	<b>20,14,35,153</b>

17 Other non-current financial liability			
Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
(i) Grants Received	16,84,15,549	18,18,56,666	18,25,80,017
<b>TOTAL</b>	<b>16,84,15,549</b>	<b>18,18,56,666</b>	<b>18,25,80,017</b>

#### 18 Financial liability

##### (i) Trade Payable

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
<b>Total outstanding :</b>	-	-	-
(i) Dues to Medium Enterprises & Small Enterprises (MSME)* ( Refer Note No 36 &	4,32,48,182	4,81,30,112	5,27,71,705
(ii)Dues other than MSME ( Refer Note No.36)	4,34,95,888	4,90,03,985	41,891
<b>TOTAL</b>	<b>8,67,44,070</b>	<b>9,71,34,097</b>	<b>5,28,13,595</b>

\* Includes Capital creditors of Rs.4,32,48,182/-, dues to micro and small enterprises.

##### 19 (ii) Other financial liability

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
(i)Current maturities of long-term debt	28,33,54,800	18,96,04,800	21,04,800
(ii) Interest accrued but not due on borrowings.	6,32,235	7,88,51,617	20,934
(iii) Salary Payable	2,29,82,973	2,38,43,720	1,62,19,386
(iv) Capital Creditors	6,19,56,248	8,06,79,443	17,45,46,136
(v) Unclaimed Salary	75,192	5,11,822	-
(vi) Interest accrued and due	12,28,58,893	90,45,205	-
(vii) Birac Grants	1,17,33,333	-	-
(viii) Slump Sale consideration to Shilpa Medicare Ltd (Refer Note No.26)	-	-	3,36,60,00,000
<b>TOTAL</b>	<b>50,35,93,674</b>	<b>38,25,36,607</b>	<b>3,55,88,91,256</b>

##### 20 Other current liability

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
(i) Tax deduction at source	1,86,98,117	47,85,006	1,03,17,469
(ii) Tax collection at source	-	86	-
(iii) ESI, Professional tax, Etc.	52,698	57,283	58,198
(iv) Provident fund payable	9,00,408	4,14,167	6,12,034
(vi) Others	-	-	26,80,000
<b>TOTAL</b>	<b>1,96,51,223</b>	<b>52,56,542</b>	<b>1,36,67,701</b>

##### 21 Provision

Particulars	As at 31st March-2021	As at 31st Dec-2020	As at 31st March-2020
(i) Provision for Expenses	80,69,308	87,71,270	59,71,812
(ii) Provision for gratuity ( Refer Note. 27)	9,67,207	-	64,432
<b>TOTAL</b>	<b>90,36,515</b>	<b>87,71,270</b>	<b>60,36,244</b>

##### 0 Revenue from operations

Particulars	As at 31st March-2021	As at 31st March-2021	As at 31st March-2020
a) Sales of Products	8,03,000	-	-
<b>TOTAL</b>	<b>8,03,000</b>	<b>-</b>	<b>-</b>

22 Other income

Particulars	As at 31st March-2021	For the Period Ended 31st Dec-20	As at 31st March-2020
(i) Interest Income on :	-		
a) Deposit with bank	7,04,747		
b) Others	-		
b) Bad debts recovered	-		
(ii) Liabilities written back	-		
(iii) Provision written back	-		
(ii) Income from sale of scrap	2,70,491	80,003	-
(iv) Others Income	3,046	-	-
(ii) Gain on Insurance claim settlement	-	-	-
(vii) Realised Gain from Redemption / Maturity of MF's	-	-	-
(vi) Entry tax refund	-	-	-
(vii) Interest rate swap on ECB	-	-	-
(v) Other Income	-	-	-
(vi) Corporate Guarantee Fees (RMPL)	-	-	-
(iv) Capital Subsidy (Grants)	24,31,135	7,23,351	-
(iiv) Profit on sale of Fixed assets	6,18,508	65,488	-
(iiv) Liability no longer required written back	20,65,252	-	-
<b>TOTAL</b>	<b>60,93,178</b>	<b>8,68,842</b>	<b>-</b>

23 Employee benefits expense

Particulars	As at 31st March-2021	For the Period Ended 31st Dec-20	As at 31st March-2020
(i) Salaries, wages, allowances and bonus	10,64,57,403	5,12,30,762	-
(ii) Contribution to provident/Gratuity and other funds	38,85,653	41,54,108	-
(iii) Staff welfare expenses	30,87,170	1,86,543	-
<b>TOTAL</b>	<b>11,34,30,225</b>	<b>5,55,71,413</b>	<b>-</b>

24 Finance costs

Particulars	As at 31st March-2021	For the Period Ended 31st Dec-20	As at 31st March-2020
<b>Interest expense on :</b>	-		
(i) Working capital facility	-	-	-
(ii) Finance cost - Corporate Guarantee	9,75,660	-	-
<b>(iii) Others</b>			
Interest on Secured Loan	1,31,30,137	-	-
Interest on Un-secured Loan	2,18,91,799	-	-
Interest Others	10,78,140	2,05,476	-
<b>TOTAL</b>	<b>3,70,75,736</b>	<b>2,05,476</b>	<b>-</b>

25 OTHER EXPENSES

Particulars	As at 31st March-2021	For the Period Ended 31st Dec-20	As at 31st March-2020
(a) ROC Expenses / Stamp Duty	6,000	4,800	26,79,200
(b) Payment to Auditors (Refer note 36)	1,85,000	-	38,000
(c) Power and fuel	1,21,22,938	13,26,849	-
(d) Repairs and maintenance	-	-	-
Plant and machinery	72,21,922	14,36,192	-
Others	67,01,907	3,98,909	-
(e) Rent	1,93,496	1,76,496	-
(f) Foreign exchange fluctuation,(gain)/ loss (net)	(88,076)	(16,987)	-
(g) Rates, taxes and fees	22,01,312	532	-
(h) Insurance	1,56,549	64,268	-
(i) Travelling and conveyance	12,25,518	9,75,843	-
(j) Contractor labour charges	34,44,951	5,42,900	-
(k) Legal & Professional fees	14,35,050	3,08,760	-
(m) Research and development expenses	2,48,58,686	1,67,11,101	-
(n) Transportation Charges	14,14,143	10,18,125	-
(p) Directors fees	60,000	-	-
(o) Professional Tax	2,500	-	-
(v) CSR expenditure	-	-	-
(v) Operating Lease ( Land)	-	-	-
(v) Security Charges	49,44,740	2,93,600	-
(w) Capital advances written-off	-	-	-
(p) Provision for expired inventory	-	4,88,033	-
(q) Miscellaneous expenses	44,49,958	13,14,937	-
<b>TOTAL</b>	<b>7,05,36,593</b>	<b>2,50,44,359</b>	<b>27,17,200</b>

**12 EQUITY SHARE CAPITAL**

Particulars	As at 31st March-2021	As at 31st March -2020
<b>Authorised Shares</b>		
30,00,000 (PY:30,00,000) equity shares of Rs.100/- each	30,00,00,000	30,00,00,000
	<b>30,00,00,000</b>	<b>30,00,00,000</b>
<b>Issued Subscribed &amp; Fully Paid Up capital</b>		
30,00,000 (PY : 1000) Equity shares of Rs.100/-each	30,00,00,000	1,00,000
<b>Total</b>	<b>30,00,00,000</b>	<b>1,00,000</b>

**12 (a) Reconciliation of the equity shares capital outstanding at the beginning and at the end of the reporting year**

Particulars	As at 31st March-2021		As at 31 March -2020	
	No of Shares	Amount	No of Shares	Amount
Shares outstanding at the beginning of the year	1,000	1,00,000	-	-
Add : Issued during the year face value Rs. 100/- each	29,99,000	29,99,00,000	1,000	1,00,000
<b>Shares outstanding at the end of the year</b>	<b>30,00,000</b>	<b>30,00,00,000</b>	<b>1,000</b>	<b>1,00,000</b>

**12 (b) Terms/rights attached to equity shares**

**Equity Shares:**

The Company has only one class of equity shares having par value of Rs. 100/- per share. Each holder of equity shares is entitled to one vote per share. In the event of liquidation, the holders of equity are entitled to receive the remaining assets of the Company, after distribution of all preferential amounts, if any. The distribution will be in proportion to the number of equity shares held by the shareholders.

**12 (c) Details of Shareholders holding more than 5% shares in the Company**

Particulars	As at 31st March-2021		As at 31st March-2020	
	No of Shares	% Holding	No of Shares	% Holding
1) Shilpa Medicare Limited	29,99,999	99.999	999	99.999

\*Note: The above does not include 1 share held by Ramakant Innani in the representative capacity on behalf of Shilpa Medicare Ltd